It is always risky to finance pharmaceutical research : if it sometimes results in a marketable product, it often leads to a dead end. Those who take the risk of help should be rewarded. For having reminded us of this obvious fact, the CEO of Sanofi, the British Paul Hudson, drew Thursday, a volley of green wood on the part of all the "patriotic economic" self-proclaimed in France – and they proliferate to the right as on the left.
However, the reasoning of Sanofi es...Article reserved to subscribers
Already a subscriber ?sign in
Not a subscriber yet ?Subscribe